Decisions at the Annual General Meeting

Decisions at the Annual General Meeting The BioPhausia Annual General Meeting on April 26 1999 authorized the Board of Directors of BioPhausia AB (publ) to decide on a new issue of Series A and/or Series B shares, whereby the issue may be effected without regard to shareholders´ preferential rights. The maximum number of shares thus issued will be 10,000,000. The Annual General Meeting decided on changes in the Articles of Association of the Company with regard to the activities of the Company, as well as revisions required by changes in the Companies Act. The Annual General Meeting decided to elect to the BioPhausia Board the following members: Ulf Holmström, Gösta Jonsson, Bertil Larsson, Torvard Laurent and Johannes Norrby. The Annual General Meeting also decided to establish a Nominating Committee, consisting of Stellan Lind, Per-Johan Björnstedt and a representative of the Swedish Association of Share Investors to propose Board candidates, as well as fees for the Board members, to shareholders at the Company's Annual General Meeting in the year 2000. At the Board Meeting following election Johannes Norrby was elected Chairman of the Board. The interim report January - March 1999 will be made public on May 25. Uppsala, April 26, 1999 Based on its contact network and know-how, primarily in connective tissue biology, BioPhausia is developing products for licensing to well-established pharmaceutical companies with strong marketing organizations. The product and project portfolio includes RescueFlow®, a resuscitation solution, Krillase® for the debridement of chronic wounds (clinical phase III), and preclinical projects in the tumor and trauma treatment areas. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/04/28/19990428BIT00410/bit0001.doc http://www.bit.se/bitonline/1999/04/28/19990428BIT00410/bit0002.pdf